Satellos Bioscience Inc. Common Stock (MSLE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Satellos Bioscience Inc. Common Stock stock (MSLE) is currently trading at $7.07. Satellos Bioscience Inc. Common Stock PE ratio is 2.85. Analyst consensus price target for MSLE is $40.00. WallStSmart rates MSLE as Sell.
- MSLE PE ratio analysis and historical PE chart
- MSLE PS ratio (Price-to-Sales) history and trend
- MSLE intrinsic value — DCF, Graham Number, EPV models
- MSLE stock price prediction 2025 2026 2027 2028 2029 2030
- MSLE fair value vs current price
- MSLE insider transactions and insider buying
- Is MSLE undervalued or overvalued?
- Satellos Bioscience Inc. Common Stock financial analysis — revenue, earnings, cash flow
- MSLE Piotroski F-Score and Altman Z-Score
- MSLE analyst price target and Smart Rating
Satellos Bioscience Inc.
📊 No data available
Try selecting a different time range
MSLE Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Satellos Bioscience Inc. Common Stock (MSLE)
MSLE trades at a significant discount to its Graham intrinsic value of $17.48, offering a 33% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Satellos Bioscience Inc. Common Stock (MSLE) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Satellos Bioscience Inc. Common Stock (MSLE) Key Strengths (0)
Supporting Valuation Data
Satellos Bioscience Inc. Common Stock (MSLE) Areas to Watch (4)
Company is destroying shareholder value
Very low institutional interest at 6.20%
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.4x book value
Satellos Bioscience Inc. Common Stock (MSLE) Detailed Analysis Report
Overall Assessment
This company scores 9/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 0 register as strengths (avg 0/10) while 4 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Institutional Own., Market Cap. Some valuation metrics including Price/Book (4.43) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -87.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -87.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MSLE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Satellos Bioscience Inc. Common Stock (MSLE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Satellos Bioscience Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Satellos Bioscience Inc. Common Stock.
Bottom Line
Satellos Bioscience Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:07:05 AM
About Satellos Bioscience Inc. Common Stock(MSLE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company is headquartered in Toronto, Canada.